Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Ponesimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OPTIMUM-LT
- Sponsors Actelion Pharmaceuticals
- 13 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2018 Planned End Date changed from 31 Mar 2022 to 2 Apr 2022.
- 16 Mar 2018 Planned primary completion date changed from 31 Mar 2022 to 2 Apr 2022.